FDA approves Ozempic to reduce risks from chronic kidney disease in diabetes patients
Ozempic, the drug that was originally approved to treat type 2 diabetes, has now also been approved by the FDA to reduce ...
Popular GLP-1 medications may have health benefits that extend beyond weight loss and blood sugar control, a new study finds
THESE MEDICATIONS ARE MOSTLY KNOWN FOR TREATING DIABETES AND OBESITY.. BUT THE F-D-A HAS APPROVED THEM FOR PREVENTING HEART ...
Diabetes drugs lower heart disease risk, raise gastro, arthritic disorders
Commonly used diabetes drugs could lower the risk of cardiometabolic conditions but heighten the risk of gastrointestinal and ...
Popular Weight Loss Drugs Could Affect Your Behavior: Scientists Conduct Genetic Investigation
A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.
Viking Therapeutics: Cooling Market Sentiments Surrounding GLP1s - Much Uncertainties Ahead
Viking Therapeutics struggles with FDA approval and scaling up. Find out why VKTX stock’s path remains uncertain, despite its ...
Viking Therapeutics: Strategic Growth and Strong Buy Rating Amidst Advancements in Obesity Drug Pipeline
Jefferies analyst Roger Song maintained a Buy rating on Viking Therapeutics (VKTX – Research Report) yesterday and set a price target of ...
Armed robbery in Revesby5d
AMA: Drug Shortages, Ozempic Study, Workforce Strain
AMA President Dr Danielle McMullen provides an update on the past week at Federal AMA. What a whirlwind week it's been!
pharmaphorum6d
Novo Nordisk, Lilly highlight oral obesity drugs at ADA
A once-weekly injectable form of the drug is sold as Wegovy and has also ... 46 weeks of treatment with their dual glucagon/GLP1 agonist survodutide (BI 456906) given as a weekly subcutaneous ...